| NCT06641414 | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). | RECRUITING | PHASE3 | 2025-01-22 | 2029-12 | 2029-06 |
| NCT06687070 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | RECRUITING | PHASE1 | 2024-12-17 | 2027-05 | 2026-05 |
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | RECRUITING | PHASE3 | 2024-11-11 | 2029-06-30 | 2027-03-31 |
| NCT06182969 | A Study of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus. | RECRUITING | PHASE1, PHASE2 | 2024-08-09 | 2026-12 | 2026-04 |
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | RECRUITING | PHASE3 | 2024-06-11 | 2029-03-26 | 2028-05-25 |
| NCT06319456 | A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | RECRUITING | PHASE3 | 2024-04-07 | 2028-08 | 2027-08 |
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CP-CML | RECRUITING | PHASE3 | 2024-02-05 | 2026-02 | 2025-12 |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | RECRUITING | PHASE3 | 2023-12-20 | 2027-10-31 | 2025-10-20 |
| NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. | RECRUITING | PHASE3 | 2023-08-31 | 2028-10-31 | 2024-12-31 |
| NCT05773586 | A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients | RECRUITING | PHASE1 | 2023-03-13 | 2026-03-15 | 2025-08-31 |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors | RECRUITING | PHASE1 | 2023-02-28 | 2027-12-31 | 2026-06-01 |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | UNKNOWN | PHASE1 | 2022-09-30 | 2025-09-30 | 2024-09-30 |
| NCT05517616 | The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects | COMPLETED | PHASE1 | 2022-09-14 | 2023-04-20 | 2022-11-01 |
| NCT05186012 | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | RECRUITING | PHASE1, PHASE2 | 2022-06-14 | 2026-03 | 2025-09 |
| NCT04893759 | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | TERMINATED | PHASE1 | 2022-01-06 | 2022-09-14 | 2022-09-14 |
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | RECRUITING | PHASE2 | 2021-12-28 | 2024-12 | 2024-09 |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | RECRUITING | PHASE1, PHASE2 | 2021-12-23 | 2024-12-01 | 2024-09-01 |
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | SUSPENDED | PHASE1, PHASE2 | 2021-08-13 | 2024-10-01 | 2024-08-12 |
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | RECRUITING | PHASE1, PHASE2 | 2021-07-30 | 2024-10-30 | 2024-07-30 |
| NCT04496349 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | RECRUITING | PHASE2 | 2021-07-12 | 2027-05-31 | 2026-05-31 |
| NCT04260217 | APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia | COMPLETED | PHASE1 | 2021-05-30 | 2025-08-13 | 2024-02-05 |
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2021-05-26 | 2027-01 | 2026-04 |
| NCT04674514 | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | UNKNOWN | PHASE1, PHASE2 | 2021-04-13 | 2024-05 | 2024-01 |
| NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | RECRUITING | PHASE1, PHASE2 | 2021-03-17 | 2024-12-31 | 2024-12-31 |
| NCT04354727 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | WITHDRAWN | PHASE1, PHASE2 | 2020-12-15 | 2023-06-15 | 2022-12-15 |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | RECRUITING | PHASE1, PHASE2 | 2020-12-04 | 2025-12-30 | 2024-12-30 |
| NCT04501120 | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML | RECRUITING | PHASE1, PHASE2 | 2020-09-28 | 2029-09 | 2028-09 |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | RECRUITING | PHASE1, PHASE2 | 2020-08-31 | 2025-12 | 2024-10-20 |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | TERMINATED | PHASE1, PHASE2 | 2020-08-20 | 2022-05-15 | 2021-08-30 |
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | RECRUITING | PHASE1 | 2020-07-06 | 2025-12-31 | 2025-12-31 |
| NCT04568265 | A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B | RECRUITING | PHASE2 | 2020-06-03 | 2025-10-31 | 2022-10-31 |
| NCT04284488 | Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2020-04-10 | 2024-04-30 | 2024-04-30 |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | RECRUITING | PHASE1 | 2020-03-02 | 2027-06-30 | 2025-10-31 |
| NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | RECRUITING | PHASE1 | 2020-01-09 | 2024-01-31 | 2024-01-31 |
| NCT04126707 | The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans | COMPLETED | PHASE1 | 2019-11-19 | 2020-01-13 | 2020-01-13 |
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | COMPLETED | PHASE2 | 2019-10-21 | 2024-08-01 | 2024-08-01 |
| NCT04001777 | A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-07-04 | 2026-06 | 2025-12 |
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-06-03 | 2025-12-31 | 2024-10-20 |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | RECRUITING | PHASE1 | 2019-05-27 | 2028-01 | 2027-12 |
| NCT03883087 | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation | UNKNOWN | PHASE2 | 2019-04-08 | 2025-02 | 2024-05 |
| NCT03883100 | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation | UNKNOWN | PHASE2 | 2019-04-08 | 2025-03 | 2024-04 |
| NCT03882281 | Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia | COMPLETED | PHASE1 | 2019-03-25 | 2019-11-16 | 2019-11-16 |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2018-08-29 | 2025-12-30 | 2025-12-30 |
| NCT03537482 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | RECRUITING | EARLY_PHASE1 | 2018-08-07 | 2025-02-15 | 2024-09-15 |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | RECRUITING | PHASE1 | 2018-07-11 | 2026-12-31 | 2025-12-31 |
| NCT03585322 | APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B | COMPLETED | PHASE1 | 2018-07-04 | 2021-10-15 | 2021-10-15 |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | TERMINATED | PHASE1 | 2017-12-01 | 2021-04-15 | 2020-11-09 |
| NCT03386526 | APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies | COMPLETED | PHASE1 | 2017-11-21 | 2022-11-30 | 2022-10-31 |
| NCT03080311 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | COMPLETED | PHASE1 | 2017-02-12 | 2020-07-17 | 2020-06-22 |
| NCT02935907 | APG-115 in Patients With Advanced Solid Tumors or Lymphomas | COMPLETED | PHASE1 | 2016-10 | 2019-06-28 | 2019-06-28 |